Proprio, an AI-enabled surgical technology company based in Seattle, has successfully secured $43 million in Series B funding from a combination of new and existing investors, including Bird B.
The company's flagship product, Paradigm, is an FDA-cleared surgical navigation platform that leverages light field technology and artificial intelligence to create real-time 3D visualisations of surgeries. This innovative approach enables surgeons to view intraoperative scans as they happen. Additionally, Proprio offers Volumetric Intelligence, a platform that integrates medical images with data from Paradigm's sensors.
With the newly acquired funds, Proprio aims to accelerate the adoption of its cutting-edge platform. Gabriel Jones, the CEO and co-founder of Proprio, expressed his excitement about this pivotal moment, as they are embarking on their first-in-human cases and preparing to introduce Paradigm to patients worldwide. He believes that these milestones demonstrate the exceptional capabilities of the Proprio Paradigm and its potential to revolutionise the field of surgery.
In 2020, Proprio successfully raised $23 million in Series A financing, reflecting the strong interest and confidence in their technology and approach.
Another player in the surgical navigation platform space is MediView XR, which employs emerging technologies like augmented reality. Their XR90 offering, recently cleared by the FDA, provides healthcare providers with a 3D visualisation of a patient's internal soft tissues, vascular, organ, and skeletal structures based on CT images. Earlier this year, MediView XR secured $15 million in strategic funding, building on a previous investment of $9.9 million just a year ago.
The surgical technology sector continues to attract substantial investments as companies like Proprio and MediView XR push the boundaries of innovation, promising enhanced surgical visualisation and improved outcomes for patients.
Click here to read the original news story.